Michelle M. Hanna
Founder and CEO
Dr. Hanna, the founder and CEO of Ribomed Biotechnologies, received her Ph.D. in Chemistry from the University of California, Davis and did her postdoctoral work in Biochemistry and Molecular Genetics as an American Cancer Society Postdoctoral Fellow at the University of California, Berkeley. She was an Assistant Professor of Biological Chemistry at the University of California Irvine College of Medicine, where she received Young Investigator awards from the American Cancer Society and the Beckman Foundation, and an Associate Professor of Biochemistry until she founded Ribomed. Dr. Hanna is the inventor of the Abscription/CAPS technology. She has been awarded over $10 million in grants and contracts and her work has resulted in numerous publications and patents. Dr. Hanna also serves on the Grant Review Board for Praespero, an autoimmune disease foundation.
genetics, genetics disorders, cancer biology